Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Revakinagene Taroretcel
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Neurotech Provides Update on BLA for NT-501 in Macular Telangiectasia
Details : NT-501 (revakinagene taroretcel) leverages is a gene therapy which delivers CNTF through an ocular implant, it is designed for the treatment of chronic retinal diseases, such as MacTel.
Brand Name : NT-501
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
November 08, 2024
Lead Product(s) : Revakinagene Taroretcel
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Revakinagene Taroretcel
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Neurotech Receives Priority Review for NT-501 as Treatment for MacTel Type 2
Details : NT-501 (revakinagene taroretcel) leverages is a gene therapy which delivers CNTF through an ocular implant, it is designed for the treatment of chronic retinal diseases, such as MacTel.
Brand Name : NT-501
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
June 20, 2024
Lead Product(s) : Revakinagene Taroretcel
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ciliary Neurotrophic Factor
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Designed to be implanted into the vitreous cavity of the eye, the investigational Ciliary Neurotrophic Factor(Renexus) implant is a tiny hollow cylindrical membrane which encapsulates human epithelial cells genetically engineered to produce CNTF continuo...
Brand Name : Renexus
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 02, 2022
Lead Product(s) : Ciliary Neurotrophic Factor
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?